Business Description
Carl Zeiss Meditec AG
ISIN : DE0005313704
Share Class Description:
XSWX:AFX: Ordinary SharesCompare
Compare
Traded in other countries / regions
AFX.Germany0DHC.UKCZMWY.USA1AFX.ItalyAFX.AustriaAFX.SwitzerlandAFX.Mexico IPO Date
2000-03-22Description
Carl Zeiss Meditec is one of the largest medical technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.24 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | 0.46 | |||||
| Interest Coverage | 11.47 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.03 | |||||
| Beneish M-Score | -2.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16.1 | |||||
| 3-Year EBITDA Growth Rate | 23.4 | |||||
| 3-Year EPS without NRI Growth Rate | 33.4 | |||||
| 3-Year FCF Growth Rate | 0.9 | |||||
| 3-Year Book Growth Rate | 14.7 | |||||
| Future 3-5Y Total Revenue Growth Rate | 5.96 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.51 | |||||
| Quick Ratio | 2.41 | |||||
| Cash Ratio | 0.07 | |||||
| Days Inventory | 199.01 | |||||
| Days Sales Outstanding | 55.17 | |||||
| Days Payable | 81.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.53 | |||||
| 3-Year Dividend Growth Rate | 19.2 | |||||
| Forward Dividend Yield % | 0.62 | |||||
| 5-Year Yield-on-Cost % | 1.03 | |||||
| Shareholder Yield % | 2.29 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.12 | |||||
| Operating Margin % | 12.86 | |||||
| Net Margin % | 9.84 | |||||
| FCF Margin % | 9.95 | |||||
| ROE % | 9.81 | |||||
| ROA % | 7.02 | |||||
| ROIC % | 7.14 | |||||
| ROC (Joel Greenblatt) % | 43.52 | |||||
| ROCE % | 13.1 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 25.66 | |||||
| Forward PE Ratio | 21.99 | |||||
| PE Ratio without NRI | 25.66 | |||||
| Shiller PE Ratio | 27.2 | |||||
| PEG Ratio | 1.31 | |||||
| PS Ratio | 2.53 | |||||
| PB Ratio | 2.45 | |||||
| Price-to-Tangible-Book | 3.63 | |||||
| Price-to-Free-Cash-Flow | 25.42 | |||||
| Price-to-Operating-Cash-Flow | 25.42 | |||||
| EV-to-EBIT | 16.81 | |||||
| EV-to-Forward-EBIT | 27.3 | |||||
| EV-to-EBITDA | 16.81 | |||||
| EV-to-Forward-EBITDA | 23.39 | |||||
| EV-to-Revenue | 2.53 | |||||
| EV-to-Forward-Revenue | 6.11 | |||||
| EV-to-FCF | 25.53 | |||||
| Price-to-Projected-FCF | 1.63 | |||||
| Price-to-DCF (FCF Based) | 5.84 | |||||
| Price-to-Median-PS-Value | 0.54 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.61 | |||||
| Price-to-Net-Current-Asset-Value | 5.38 | |||||
| Earnings Yield (Greenblatt) % | 5.95 | |||||
| FCF Yield % | 4 | |||||
| Forward Rate of Return (Yacktman) % | 20.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Carl Zeiss Meditec AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 1,979.435 | ||
| EPS (TTM) (CHF) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0.53 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (CHF) | 0 | ||
| 20-Day SMA (CHF) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (CHF) | 174.55 - 174.55 | ||
| Shares Outstanding (Mil) | 89.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Carl Zeiss Meditec AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Carl Zeiss Meditec AG Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Carl Zeiss Meditec AG Frequently Asked Questions
What is Carl Zeiss Meditec AG(XSWX:AFX)'s stock price today?
The current price of XSWX:AFX is CHF174.55. The 52 week high of XSWX:AFX is CHF174.55 and 52 week low is CHF174.55.
When is next earnings date of Carl Zeiss Meditec AG(XSWX:AFX)?
The next earnings date of Carl Zeiss Meditec AG(XSWX:AFX) is 2024-12-12 Est..
Does Carl Zeiss Meditec AG(XSWX:AFX) pay dividends? If so, how much?
The Dividend Yield %  of Carl Zeiss Meditec AG(XSWX:AFX) is 0.53% (As of Today), Highest Dividend Payout Ratio of Carl Zeiss Meditec AG(XSWX:AFX) was 0.49. The lowest was 0.19. And the median was 0.33. The  Forward Dividend Yield % of Carl Zeiss Meditec AG(XSWX:AFX) is 0.62%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers